BioArctic: A bit stronger Q4 than expected, BMS deal a validation of BT technology - Redeye

Redeye return with a research update following BioArctic's Q4 report and recent events, including the significant BMS deal and EU process, which overall leads to a slightly raised valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1078472/bioarctic-a-bit-stronger-q4-than-expected-bms-deal-a-validation-of-bt-technology?utm_source=finwire&utm_medium=RSS